Sec61

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Downregulation and upregulation, ISCB Senior Scientist Award, Annual general meeting, Safety, ALT, Cohort, UPCR, AIH, Immunosuppression, Clinical trial, Patient, KZR, OLE, Week, American College of Rheumatology, Immunotherapy, Mount Everest, G&A, Pharmacokinetics, Polymyositis, American College, PD-1, University, Dermatomyositis, Lupus nephritis, SITC, Total, Autoimmune hepatitis, Growth, CRR, Congress, ACR, APLAR, Society, Sec61, Pharmaceutical industry, Rheumatology, Kezar Pavilion

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • In addition, Kezar recently announced a strategic restructuring to prioritize long-term growth and focus resources on its clinical-stage programs.
  • Actions to prioritize clinical programs and implement cost saving measures are expected to extend Kezar’s cash runway into late 2026.
  • Research and development expenses for the third quarter of 2023 increased by $9.8 million to $23.7 million compared to $13.9 million in the third quarter of 2022.

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Society, Assistant, KZR, Annual general meeting, Autoimmune hepatitis, American College of Rheumatology, ACR, Asian literature, CRR, National Kidney Foundation, Cohort, Indiana University, Protein, Event, SITC, Patient, American College, AST, ASN, Research, UPCR, G&A, Week, Safety, Clinical trial, KCR, Total, Immunotherapy, NKF, Lupus nephritis, Pharmacokinetics, ALT, AIH, Sec61, Kezar Pavilion, Pharmaceutical industry, Vaccine, Video game, LN, Medicine

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.
  • “We made tremendous progress in both of our first-in-class programs during 2022,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer.
  • Research and development expenses for the fourth quarter of 2022 increased by $5.1 million to $14.9 million compared to $9.8 million in the fourth quarter of 2021.
  • General and administrative (G&A) expenses for the fourth quarter of 2022 increased by $0.9 million to $5.2 million compared to $4.3 million in the fourth quarter of 2021.

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 7, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Disease, Financial compensation, Sec61, Lupus nephritis, Kezar Stadium, Employment, Pharmaceutical industry

The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Kezars 2022 Inducement Plan and the stock option agreement covering the grants.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders.
  • KZR-261 is the first anti-cancer clinical candidate from the companys platform targeting the Sec61 translocon and the protein secretion pathway.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

Retrieved on: 
Monday, November 14, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EOS, Patient, Clinical trial, Plasma protein binding, Week, CD163, ORR, Lupus, EGFR, Dialysis, American College of Rheumatology, American College, DNA, UPCR, Kidney, Lupus nephritis, Death, Disease, Safety, Immune system, Degenerative disease, CRR, ACR, Inflammation, Skin manifestations of sarcoidosis, Chronic kidney disease, Immunosuppression, SLE, EOT, Biomarker, Diagnosis, Phase 1, Risk, Sec61, Proteinuria, Expressway Authority of Thailand, Pharmaceutical industry, Aluminium, Medical imaging, Synthetic oil, Medical device, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 11, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Employment, Disease, Kezar Stadium, Board, Lupus nephritis, Sec61, Safety, Financial compensation, Pharmaceutical industry

The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option is subject to the terms and conditions of Kezars 2022 Inducement Plan and the stock option agreement covering the grant.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
  • KZR-261 is the first anti-cancer clinical candidate from the companys platform targeting the Sec61 translocon and the protein secretion pathway.

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, EOS, IND, Lupus, Immunotherapy, Research, SLE, PD-1, EGFR, Company, UPCR, Quality of life, Forward-looking statement, Expressway Authority of Thailand, Tumor microenvironment, Annual general meeting, Food, Society, Total, Kezar Pavilion, Degenerative disease, U.S. Securities and Exchange Commission, Pharmacokinetics, Inflammation, Liver, Patient, Conditional sentence, American College, Private Securities Litigation Reform Act, Nasdaq, Week, AST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lupus nephritis, Clinical trial, ACR, ALT, Autoimmune hepatitis, CRR, American College of Rheumatology, Sec61, EOT, Safety, Association, Proteinuria, Biomarker, Disease, ASN, Immune system, AIH, ORR, SITC, LLC, Pharmaceutical industry

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Kezar presented positive complete results for the 37-week Phase 2 MISSION clinical trial at the American Society of Nephrologys (ASN) Kidney Week 2022 Annual Meeting.
  • General and administrative expenses for the third quarter of 2022 increased by $1.0 million to $5.0 million compared to $4.0 million in the third quarter of 2021.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, Lupus nephritis, Safety, Sec61, Disease, Pharmaceutical industry, Kezar Stadium

(Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.

Key Points: 
  • (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.
  • Webcasts from the presentations will be available on the Events & Presentations section of the Companys website at www.kezarlifesciences.com .
  • Following the events, archived webcasts will be available on the Kezar website for 90 days.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EOS, Patient, ORR, EOT, Immunosuppression, Private Securities Litigation Reform Act, DNA, Dialysis, Week, Lupus nephritis, Society, Association, Glomerular filtration rate, Death, Safety, Biomarker, CRR, SLE, Disease, Phase 1, EGFR, Nasdaq, Sec61, UPCR, Chronic kidney disease, Annual general meeting, ASN, CD163, U.S. Securities and Exchange Commission, Clinical trial, Autoimmune hepatitis, Forward-looking statement, Risk, Expressway Authority of Thailand, Inflammation, Degenerative disease, Proteinuria, Kidney, Plasma protein binding, Diagnosis, Treatment, Lupus, Pharmaceutical industry, Medical imaging, Synthetic oil, Dentistry, LN

The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.

Key Points: 
  • The MISSION Phase 2 clinical trial was an open-label study designed to demonstrate the responder rate of zetomipzomib in patients with active LN.
  • Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a significant difference from other recently published clinical trials in LN.
  • In the MISSION Phase 2 clinical trial, 17 of 21 enrolled patients reached end-of-treatment at Week 25 and end-of-study at Week 37.
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis.

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting

Retrieved on: 
Friday, October 14, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ASN, Disease, Lupus nephritis, Pathology, Lee, Ohio State University Wexner Medical Center, Degenerative disease, Society, FACP, Patient, Division, Annual general meeting, Nasdaq, Treatment, MD, Immunosuppression, Sec61, Congress, Safety, 2021 Essex County Council election, Associate, International Association for Mission Studies, Ohio State University, FASN, Medicine, List of life sciences, Pharmaceutical industry, Nephrology

Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.

Key Points: 
  • Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial.
  • There will be additional MISSION data included in the poster presentation that are not available in the abstract.
  • Following the conference, the presentation materials will be available in the Scientific Publications section of Kezar Life Sciences website at www.kezarlifesciences.com .
  • Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis.

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, October 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Autoimmune hepatitis, Lupus nephritis, Disease, Kezar Stadium, Financial compensation, Board, Sec61, List of life sciences, Safety, Employment, Pharmaceutical industry

The stock options were granted as an inducement award material to the individuals entering employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as an inducement award material to the individuals entering employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of Kezars 2022 Inducement Plan and the stock option agreement covering the grants.
  • Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
  • KZR-261 is the first anti-cancer clinical candidate from the companys platform targeting the Sec61 translocon and the protein secretion pathway.